The pharmacology of weight gain with antipsychotics

Journal of Clinical Psychiatry

Volumn 62, Issue SUPPL. 7, 2001, Pages 4-10

  Casey, D E ^a   Zorn, S H ^a  

^a PORTLAND VA MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 DIPROPYLAMINO 8 HYDROXYTETRALIN; ALPHA 1 ADRENERGIC RECEPTOR BLOCKING AGENT; AMITRIPTYLINE; ANTIOBESITY AGENT; BUSPIRONE; CHLORPROMAZINE; CLOZAPINE; CYPROHEPTADINE; DOPAMINE 2 RECEPTOR; DOPAMINE 2 RECEPTOR BLOCKING AGENT; FENFLURAMINE; HALOPERIDOL; HISTAMINE H1 RECEPTOR; HISTAMINE H1 RECEPTOR ANTAGONIST; LEPTIN; LOXAPINE SUCCINATE; MIRTAZAPINE; MOLINDONE; MUSCARINIC RECEPTOR; MUSCARINIC RECEPTOR BLOCKING AGENT; NEUROLEPTIC AGENT; OLANZAPINE; PERPHENAZINE; PRAZOSIN; QUETIAPINE; RISPERIDONE; SEROTONIN 1A AGONIST; SEROTONIN 1A RECEPTOR; SEROTONIN 1D ANTAGONIST; SEROTONIN 1D RECEPTOR; SEROTONIN 2A ANTAGONIST; SEROTONIN 2A RECEPTOR; SEROTONIN 2C ANTAGONIST; SEROTONIN 2C RECEPTOR; SERTINDOLE; SIBUTRAMINE; THIORIDAZINE; ZIPRASIDONE;

ADRENERGIC SYSTEM; BODY WEIGHT; CLINICAL TRIAL; DOPAMINERGIC SYSTEM; DRUG INDUCED DISEASE; EXTRAPYRAMIDAL SYMPTOM; GASTROINTESTINAL SYMPTOM; HISTAMINE RELEASE; HUMAN; HYPOTENSION; MONOAMINERGIC SYSTEM; NEUROTRANSMISSION; OBESITY; PRIORITY JOURNAL; PSYCHOSIS; RECEPTOR BINDING; REVIEW; SEDATION; SEROTONINERGIC SYSTEM; WEIGHT GAIN;

ANIMALS; ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; CLOZAPINE; DIBENZOTHIAZEPINES; EATING; HUMANS; PIPERAZINES; PIRENZEPINE; PSYCHOTIC DISORDERS; RATS; RECEPTORS, NEUROTRANSMITTER; SCHIZOPHRENIA; THIAZOLES; WEIGHT GAIN;

EID: 0035029445     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (58)

1. Antipsychotic-induced weight gain: A comprehensive research synthesis
2. Antipsychotics from theory to practice: Integrating clinical and basic data
3. Signals that regulate food intake and energy homeostasis
4. Pharmacology of appetite suppression
5. A review of central 5-HT receptors and their function
6. The serotonin precursor 5-hydroxytryptophan elevates serum leptin levels in mice
7. Human obesity is associated with a chronic elevation in brain 5-hydroxytryptamine turnover
8. Characteristics of feeding induced by the serotonin agonist 8-hydroxy-2-(di-n-propylamino) tetralin (8-OH-DPAT)
9. Serotonergic control of the organization of feeding and satiety
10. Low doses of the putative serotonin agonist 8-hydroxy-2-(di-n-propylamino) tetralin (8-OH-DPAT) elicit feeding in the rat
11. 1A agonist 8-OH-DPAT on food intake in food-deprived rats
12. 1A receptor interactions in feeding behavior and neuroendocrine regulation
13. 1A receptor agonists as antidepres-sants
14. 1B receptors
15. Infusion of the 5-hydmxytryptamine agonists RU24969 and TFMPP into the paraventricular nucleus of the hypothalamus causes hypophagia
16. The role of 5-HT receptors in the effect of D-fenfluramine on feeding patterns in the rat
17. 2C receptor modulation and the treatment of obesity
18. Absence of fenfluramine-induced anorexia and reduced c-Fos induction in the hypothalamus and central amygdaloid complex of serotonin 1B receptor knock-out mice
19. 2 receptor subtypes: A family reunited?
20. 2C receptor antagonist
21. 2C receptor antagonist
22. Molecular manipulations as tools for enhancing our understanding of 5-HT neurotransmission
23. 2C receptor activation decreases appetite and body weight in obese subjects
24. 2B receptor agonist, causes hyperphagia and reduced grooming in rats
25. 3 receptor agonists on food intake in food-deprived and 2-deoxy-D-glucose-treated rats
26. 5-Hydroxytryptaminergic receptor agonists: Effects on neuropeptide Y potentiation of feeding and respiratory quotient
27. Hypothalamic neuronal histamine: Implications of its homeostatic control of energy metabolism
28. Involvement of the histaminergic system in leptin-induced suppression of food intake
29. Neuronal glucoprivation enhances hypothalamic histamine turnover in rats
30. Neuronal histamine in the hypothalamus suppresses food intake in rats
31. Histamine regulates food intake through modulating norepinephrine release in the para-ventricular nucleus
32. Effects of cyproheptadine on the feeding and satiety centers in the rat
33. How do antidepressants affect serotonin receptors? The role of serotonin receptors in the therapeutic and side effect profile of the SSRIs
34. Mirtazapine: A review of its use in major depression
35. Modulation of feeding by hypothalamic paraventricular nucleus alpha 1- and alpha 2-adrenergic receptors
36. Investigation of the mechanisms underlying the hypophagic effects of the 5-HT and norepinephrine reuptake inhibitor, sibutramine, in the rat
37. Identification of a three-amino acid deletion in the alpha2B-adrenergic receptor that is associated with reduced basal metabolic rate in obese subjects
38. Dopamine receptor subtype agonists and feeding behavior
39. Strategies and potential molecular targets for obesity treatment
40. Sibutramine: A novel anti-obesity drug: A review of the pharmacological evidence to differentiate it from D-amphetamine and D-fenfluramine
41. Drug-produced obesity: Experiences with chlorpromazine, perphenazine and clopenthixol
42. Weight gain associated with psychotropic drugs
43. The effect of antipsychotic drugs on body weight: A retrospective review
44. Clozapine-induced weight gain: Prevalence and clinical relevance
45. Differential effect of clozapine on weight: A controlled study
46. Novel antipsychotics: Comparison of weight gain liabilities
47. Weight gain: Side effect of atypical neuroleptics?
48. A comparative review of new antipsychotics
49. Body weight and leptin plasma levels during treatment with antipsychotic drugs
50. Receptor interactions of new antipsychotics: Relation to pharmacodynamic and clinical effects
51. The role of serotonin in antipsychotic drug action
52. Ziprasidone (CP88,059): A new antipsychotic with combined dopamine and serotonin receptor antagonist activity
53. Pharmacological and neurochemical studies with the new antipsychotic ziprasidone
54. The novel antipsychotic ziprasidone has a unique human receptor binding profile compared to other agents
55. Preclinical pharmacology of neuroleptics: Focus on new generation compounds
56. Ziprasidone: A novel antipsychotic with unique pharmacology and therapeutic potential
57. Pharmacological profile of neuroleptics at human monoamine transporters
58. The relationship of pharmacology to side effects